Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1693-1701

  Gilewski, Teresa ^a,c   Adluri, Sucharita ^b   Ragupathi, Govindaswami ^b   Zhang, Shengle ^b   Yao, Tzy Jyun ^c   Panageas, Katherine ^c   Moynahan, Maryellen ^a   Houghton, Alan ^b   Norton, Larry ^a   Livingston, Philip O ^b  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b Department of Medicine   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KEYHOLE LIMPET HEMOCYANIN; MUCIN; QS 21;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CELL STRAIN MCF 7; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AMINO ACID SEQUENCE; ANTIBODIES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CANCER VACCINES; DIARRHEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOLOGIC DISEASES; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NAUSEA; NEOPLASM STAGING; PEPTIDE FRAGMENTS; SKIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0034071575     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Henderson, I. C., Garber, J. E., Breitmeyer, J. B., Hayes, D. F., and Harris, J. R. Comprehensive management of disseminated breast cancer. Cancer (Phila.), 66: 1439-1448, 1990.
2. Cold, S., Jensen, N. V., Brinker, H., and Rose, C. The influence of chemotherapy on survival after recurrence in breast cancer: a population-based study of patients treated in the 1950s, 1960s, and 1970s. Eur. J. Cancer, 29A: 1146-1152, 1993.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 1-15 and 71-85, 1992.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
5. Antman, K. H., Rowlings, P. A., Vaughan, W. P., Pelz, C. J., Fay, J. W., Fields, K. K., Freytes, C. O. Gale, R. P., Hillner, B. E., Holland, H. K., Kennedy, M. J., Klein, J. P., Lazarus, H. M., McCarthy, P L., Saez, R., Spitzer, G., Stadtmauer, E. A., Williams, S. F., Wolff, S., Sobocinski, K. A., Armitage, J. O., and Horowitz, M. M. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol., 15: 1870-1879, 1997.
6. Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., Jungi, W. F., Thurlimann, B., Cavalli, F., Obrecht, J. P., Leyuraz, S., Alberto, P., Adam, H., Varini, M., Loehnert, T., Senn, H. J., Metzger, V., and Brunner, K., for the Swiss Group for Clinical Cancer Research. First isolated locoregional recurrence following mastectomy for breast cancer: results of a Phase III multicenter study comparing treatment with observation after excision and radiation. J. Clin. Oncol., 12: 2071-2077, 1994.
7. Greenberg, P. A. C., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., and Buzdar, A. U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14: 2197-2205, 1996.
8. Hortobagyi, G. N., and Budzar, A. U. Locally advanced breast cancer: a review including the M. D. Anderson experience. In: J. Ragaz, I. M. Ariel (eds.), High-risk Breast Cancer, pp. 382-415. Berlin: Springer-Verlag, 1991.
9. Chan, D. W., Beveridge, R. A., Muss, H., Fritsche, H. A., Hortobagyi, G., Theriault, R., Kiang, D., Kennedy, B. J., and Evelegh, M. Use of truquant BR radioirnmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol., 15: 2322-2328, 1997.
10. Hayes, D. F. Tumor markers for breast cancer. Ann. Oncol., 4: 807-819, 1993.
11. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol., 14: 2843-2877, 1996.
12. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of herceptin (Humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 98a, 1998.
13. Lloyd, K. O. Blood group antigens as markers for normal differentiation and malignant changes in human tissues. Am. J. Clin. Pathol., 87: 129-139, 1987.
14. Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer, 73: 42-49, 1997.
15. Zhang, S., Zhang, H. S., Cordon-Cardo, C., Reuter, V. E., Singhal, A. K., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer, 73: 50-56, 1997.
16. Zhang, S., Zhang, H. S., Cordon-Cardo, C., Ragupathi, G., and Livingston, P. O. Selection of tumor antigens as targets for immune attack using immunohistochemistry. III. Protein antigens. Clin. Cancer Res., 4: 2669-2676, 1998.
17. Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magadan-Blander, J., and Barratt-Boyes, S. M. MUC1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev., 145: 61-89, 1995.
18. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., and Lamport, D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47: 5476-5482, 1987.
19. Zotter, S., Hageman, P. C., Lossnitzer, A., Mooi, W. J., and Kilgers, J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer (Phila.) Rev., 11: 55-101, 1988.
20. Barnd, D. L., Lan, M. S., Metzgar, R. S., and Finn, O. J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 86: 7159-7163, 1989.
21. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., and Burchell, J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem., 263: 12820-12823, 1988.
22. Barratt-Boyes, S. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother., 43: 142-151, 1996.
23. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. T., and Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J. Biol. Chem., 271: 33325-33334, 1996.
24. Burchell, J., Taylor-Papadimitriou, J., Boshell, M., Gendler, S., and Duhig, T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer, 44: 691-696, 1989.
25. Gendler, S. J., Lancaster, C. A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E., and Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem., 265: 15286-15293, 1990.
26. Hareuveni, M., Gautier, C., Kieny, M. P., Wreschner, D., Chambon, P., and Lathe, R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl. Acad. Sci. USA, 87: 9498-9502, 1990.
27. Ding, L., Lalani, E. N., Reddish, M., Koganty, R., Wong, T., Samuel, J., Yacyshyn, M. B., Meikle, A., Fung, P. Y. S., Taylor-Papadimitriou, J., and Longenecker, B. M. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother., 36: 9-17, 1993.
28. Zhang, S., Graeber, L. A., Helling, F., Ragupathi, G., Adluri, S., Lloyd, K. O., and Livingston, P. O. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res., 56: 3315-3319, 1996.
29. Apostolopolous, V., Xing, P. X., and McKenzie, I. F. C. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res., 54: 5186-5193, 1994.
30. Apostolopolous, V., Popovski, V., and McKenzie, I. F. C. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J. Immunother., 21: 109-113, 1998.
31. Graham, R. A., Burchell, J. M., Beverley, P., and Taylor-Papadimitriou, J. Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer, 65: 664-670, 1996.
32. Pecher, G., and Finn, O. J. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl. Acad. Sci. USA, 93: 1699-1704, 1996.
33. Barratt-Boyes, S. M., Kao, H., and Finn, O. J. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J. Immunother., 21: 142-148, 1998.
34. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F. C., Bast, R. C., and Finn, O. J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 57: 2908-2916, 1991.
35. Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., and Finn, O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res., 54: 2856-2860, 1994.
36. von Mensdorff-Pouilly, S., Gourevitch, M. M., Kenemans, P., Verstraeten, A. A., Litvinov, S. V., van Kamp, G. J., Meijer, S., Vermorken, J., and Hilgers, J. Humoral immune response to polymorphic epithelial mucin (MUC1) in patients with benign and malignant breast tumours. Eur. J. Cancer, 32A: 1325-1331, 1996.
37. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol., 146: 431-437, 1991.
38. Livingston, P. O., and Ragupathi, G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol. Immunother., 45: 10-19, 1997.
39. Livingston, P. O., Adluri, S., Helling, F., Yao, T. J., Kensil, C. R., Newman, M. J., and Marciani, D. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet hemocyanin conjugate vaccine in patients with malignant melanoma. Vaccines, 12: 1275-1280, 1994.
40. Yao, T. J., Begg, C. B., and Livingston, P. O. Optimal sample size for a series of pilot trials of new agents. Biometrics, 52: 992-1001, 1996.
41. Hortobagyi, G. N., Buzdar, A. U., Frye, D., Hug, V., Fraschini, G., Ames, F. C., Montague, E., Gutterman, J. U., and Martin, R. G. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer (Phila.), 60: 2596-2604, 1987.
42. Aisner, J., Weinberg, V., Perloff, M., Weiss, R., Perry, M., Korzun, A., Ginsberg, S., and Holland, J. F. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. J. Clin. Oncol., 5: 1523-1533, 1987.
43. Giuliano, A. E., Sparks, F. C., Patterson, K., Spears, I., and Morton, D. L. Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. J. Surg. Oncol., 31: 255-259, 1986.
44. Buzdar, A. U., Blumenschein, G. R., Smith, T. L., Powell, K. C., Hortobagyi, G. N., Yap, H. Y., Schell, F. C., Barnes, B. C., Ames, F. C., Martin, R. G., and Hersh, E. M. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without bacillus calmette-guerin and with or without irradiation in operable breast cancer. Cancer (Phila.), 53: 384-389, 1984.
45. MacLean, G. D., Reddish, M., Koganty, R. R., Wong, T., Gandhi, S., Smolenski, M., Samuel, J., Nabholtz, J. M., and Longenecker, B. M. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus detox adjuvant. Cancer Immunol. Immunother., 36: 215-222, 1993.
46. Hanisch, F. G., Uhlenbruck, G., Peter-Katalinic, J., Egge, H., Dabrowski, J., and Dabrowski, U. Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. J. Biol. Chem., 264: 872-883, 1989.
47. Jerome, K. R., Domenech, N., and Finn, O. J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol., 151: 1654-1662, 1993.
48. Livingston, P. O., Zhang, S., and Lloyd, K. O. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother., 45: 1-9, 1997.
49. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
50. McKolanis, J. R., Pecher, G., Lotze, M. J., and Finn, O. J. Mucin reactive CTL induced by in vivo immunization. Proc. Am. Assoc. Cancer Res., 37: 466, 1996.
51. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T. A Phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res., 63: 298-304, 1996.
52. Karanikas, V., Hwang, L., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., and McKenzie, I. F. C. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest., 100: 2783-2792, 1997.
53. Adluri, S., Gilewski, T., Zhang, S., Ramnath, V., Ragupathi, G., and Livingston, P. Specificity analysis of sera from breast cancer patients vaccinated with MUC1 KLH plus QS-21. Br. J. Cancer, 79: 1806-1812, 1999.
54. Price, M. R., Hudecz, F., O'Sullivan, C., Baldwin, R. W., Edwards, P. M., and Tendler, S. J. B. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol. Immunol., 27: 795-802, 1990.